Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Steyr – page 16

449 clinical trials in Steyr, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Steyr at a glance
449
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

449 trials in Steyr

Open in trial search

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Systemic scleroderma+1

Not yet recruiting

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Scleroderma Research Foundation

Partial seizures

Not yet recruiting

Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Narcolepsy

Not yet recruiting

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Oveporexton
  • Sponsor:Takeda Development Center Americas Inc.

Conjunctivitis allergic

Not yet recruiting

Study on the Effectiveness and Safety of PQ Birch for Patients with Seasonal Allergic Rhinitis or Rhinoconjunctivitis from Birch Pollen

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Allergy Therapeutics (UK) Limited

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Efficacy of neoadjuvant sacituzumab govitecan versus standard drug combination in patients with endocrine non‑responsive ER+/HER2‑negative early breast cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astrazeneca AB

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Non-small cell lung cancer

Not yet recruiting

Ivonescimab with drug combination in patients with asymptomatic brain metastases from non‑small cell lung cancer – randomized phase II trial

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Steyr

What the registry says about research in the country

01 Oncology - Blood Cancers

Innovative research focusing on multiple myeloma treatment approaches, including maintenance therapy post stem-cell transplantation and comparing different administration methods for targeted therapies. Studies also investigate new treatments for Hodgkin Lymphoma with emphasis on reducing toxicity while maintaining efficacy.

  • Multiple Myeloma Treatments
  • Hodgkin Lymphoma Therapy
  • Stem Cell Transplantation

Advanced clinical research evaluating novel drug combinations and administration routes to improve patient outcomes.

02 Breast Cancer Research

Comprehensive studies examining treatments for ER-positive, HER2-negative breast cancer, including both early-stage and advanced disease. Research focuses on novel therapeutic agents and extended treatment strategies to prevent recurrence.

  • Early Breast Cancer Treatment
  • Advanced Breast Cancer Therapy
  • Endocrine Therapy Innovation

Trials aim to improve current treatment standards and evaluate new therapeutic options for breast cancer patients.

03 Pain Management Studies

Extensive research into chronic pain conditions, including diabetic polyneuropathy, post-operative neuropathy, and chronic back pain. Studies evaluate new treatment approaches for various types of neuropathic and musculoskeletal pain.

  • Neuropathic Pain Treatment
  • Chronic Back Pain Management
  • Post-operative Pain Control

Investigations focus on developing effective add-on treatments for chronic pain conditions to improve patient quality of life.

04 Pancreatic Cancer Research

Advanced studies in metastatic pancreatic ductal adenocarcinoma, evaluating novel combination therapies to improve survival rates. Research focuses on comparing standard treatments with new therapeutic approaches.

  • Metastatic Disease Treatment
  • Combination Therapy Assessment
  • Survival Rate Improvement

Clinical trials aim to enhance treatment outcomes for patients with advanced pancreatic cancer.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.